Acceleron and Celgene have initiated a second phase 2 clinical study of ACE-011. It is intended to treat chemotherapy-induced anemia in patients with metastatic breast cancer. Reportedly, phase
Foresight has reported the dosing of first patient in a viral conjunctivitis clinical trial. Foresight’s lead compound, FST-100, will be tested in a placebo-controlled, masked, and randomized multicenter
Raptor and TorreyPines have entered into a merger agreement. As per the deal, the merged company will be named – Raptor and will be headquartered in California. Under
Sanofi-aventis has reported that Multaq (dronedarone) 400mg tablets, for atrial fibrillation or atrial flutter, is now available in the US. Multaq is an anti-arrhythmic drug indicated to reduce
CytRx has provided the results demonstrating that its cancer drug candidate – INNO-206 caused significant tumor shrinkage in an animal model of ovarian cancer. INNO-206, to be used
GeneGo has received grant from Natinal Institute of Health to develop an integrated systems pharmacology platform for pharmacogenomic research. The Small Business Innovation Research (SBIR) grant will be
Watson has signed a licensing agreement with GeneraMedix for the exclusive US marketing rights to a generic version of Ferrlecit (sodium ferric gluconate complex in sucrose injection). The
ARIAD has provided the preliminary findings from two ongoing clinical trials. The study evaluated oral ridaforolimus in combination with trastuzumab (Herceptin) in patients with resistant, metastatic breast cancer
The University of Queensland’s Institute for Molecular Bioscience (IMB) and Life Technologies have formed a scientific research collaboration to study pancreatic and ovarian cancer in Australia. The study
Osiris has received a $750,000 milestone payment from the Juvenile Diabetes Research Foundation (JDRF), for progress made on a phase II clinical trial. The study is to evaluate
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.